Telomir Pharmaceuticals appoints Alan Weichselbaum as CFO; prior CFO Michelle Yanez departs

Telomir Pharmaceuticals, Inc.

Michelle Yanez and Telomir mutually agreed to her resignation as CFO, Treasurer, Secretary effective May 16, 2025; no disagreement.
Alan Weichselbaum appointed CFO starting May 19, 2025; part-time role (30 hrs/week), salary $60,000/year.
Weichselbaum receives 50,000 stock options vesting over 12 months (25k at 6 months, 25k at 12 months).
Weichselbaum concurrently serves as CFO of MIRA Pharmaceuticals and CEO of Wexus Group.
Employment is at-will, remote from New York, subject to background/reference check.

item 1.01item 5.02item 3.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michelle Yanez

Chief Financial Officer

TELO · Telomir Pharmaceuticals, Inc.

Effective: 2025-05-16
Successor: Alan Weichselbaum
Filed: May 21, 2025 23:59 UTC

Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of Telomir Pharmaceuticals, Inc. (the “Company”), effective on that date.

Appointed

Alan Weichselbaum

Chief Financial Officer

TELO · Telomir Pharmaceuticals, Inc.

Effective: 2025-05-19
Filed: May 21, 2025 23:59 UTC

On May 15, 2025, the Company entered into an Employment Agreement (the “Employment Agreement”) with Mr. Weichselbaum to serve as chief financial officer of the Company beginning on May 19, 2025 (the “Start Date”).

Source: SEC EDGAR

accession 0001641172-25-011938

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.